Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Attention Deficit Hyperactivity Disorder
Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
November 5th, 2007
Shire plc , the market leader in Attention Deficit Hyperactivity Disorder (ADHD), announced that it will present key scientific data on its ADHD treatments at a major scientific and educational meeting of child and adolescent psychiatrists to be held October 23-28 in Boston. "The Shire studies to be presented are indicative of our continuous efforts to provide a diverse range of innovative ADHD treatments," said Eliseo Salinas, M.D., Chief Scientific Officer for Shire. "We are proud to be sharing our new scientific data with the medical community, which include results of the first VYVANSE(TM) study in adults with ADHD and findings from a 12-month study on DAYTRANA(TM),...
Source: Health & Medicine Week (2007-11-05)
|
